MV BioTherapeutics to present at the 6th Microbiome Movement - Drug Development Europe

We are happy to announce that Fabio Grassi (MV BioTherapeutics founder) has been invited to contribute to the 6^thMicrobiome Movement – Drug Development Summit Europe 2022 in London during January 25^th-27^th, 2022.

The presentation has been included in stream A titled “Understanding mechanisms of action & preclinical development” the 26^th at 13.45.

Microbiota Adaptation via Secretory IgA to Correct Dysbiosis

• Learn the unique mechanism to enhance secretory IgA generation in the gut by the ATP degrading enzyme apyrase
• Individual gut microbiota adaptation by enhanced secretory IgA in different pathophysiological conditions
• Conversion of non-responders to responders to immune checkpoint blockade by an apyrase-expressing biotherapeutic